{"id":1602,"date":"2023-06-25T17:27:16","date_gmt":"2023-06-25T17:27:16","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/acebutolol\/"},"modified":"2023-06-25T19:57:54","modified_gmt":"2023-06-25T19:57:54","slug":"acebutolol","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/acebutolol\/","title":{"rendered":"Acebutolol"},"content":{"rendered":"

<\/p>\n

Acebutolol<\/h1>\n

CLINICAL USE<\/h3>\n

Beta-adrenoceptor blocker:<\/p>\n

  • Hypertension<\/li>\n
  • Angina<\/li>\n
  • Arrhythmias
    \n

    DOSE IN NORMAL RENAL FUNCTION<\/h3>\n<\/li>\n
  • Hypertension: 400 mg once a day or 200 mg twice a day, increased after 2 weeks to 400 mg twice daily if necessary<\/li>\n
  • Angina: 400 mg once a day, or 200 mg twice daily initially. Increase up to 300 mg 3 times daily; maximum 1200 mg<\/li>\n
  • Arrhythmias: 400\u20131200 mg\/day (in 2\u20133 divided doses)
    \n

    PHARMACOKINETICS<\/h3>\n<\/li>\n
  • Molecular weight                           :336.4 (372.9 as hydrochloride)<\/li>\n
  • %Protein binding                           :26<\/li>\n
  • %Excreted unchanged in urine     : 55<\/li>\n
  • Volume of distribution (L\/kg)       :1.2<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :3\u20134 (8\u201313 for active metabolite)\/Increased (32 for active metabolite)
    \n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n

    25\u201350 Dose as in normal renal function, but frequency should not exceed once daily in renal impairment10\u201325 50% of normal dose, but frequency should not exceed once daily in renal impairment<\/li>\n

  • <10           : 30\u201350% of normal dose, but frequency should not exceed once daily in renal impairment
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :Unknown dialysability. Dose as in GFR <10 mL\/min<\/li>\n
  • HD                             :Dialysed. Dose as in GFR <10 mL\/min<\/li>\n
  • HDF\/high flux   :Dialysed. Dose as in GFR <10 mL\/min<\/li>\n
  • CAV\/VVHD      :Dialysed. Dose as in GFR=10\u201325 mL\/min
    \n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugs<\/li>\n

  • Anaesthetics: enhanced hypotensive effect<\/li>\n
  • Analgesics: NSAIDs antagonise hypotensive effect<\/li>\n
  • Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone<\/li>\n
  • Antidepressants: enhanced hypotensive effect with MAOIs<\/li>\n
  • Antihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin<\/li>\n
  • Antimalarials: increased risk of bradycardia with mefloquineAntipsychotics enhanced hypotensive effect with phenothiazines<\/li>\n
  • Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil<\/li>\n
  • Diuretics: enhanced hypotensive effect<\/li>\n
  • Moxisylyte: possible severe postural hypotensionSympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine<\/li>\n
  • Tropisetron: increased risk of ventricular arrhythmias \u2013 use with caution
    \n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    \u2013<\/p>\n

    Route<\/h4>\n

    Oral<\/p>\n

    Rate of Administration<\/h4>\n

    N\/A<\/p>\n

    Comments<\/h4>\n

    \u2013<\/p>\n

    OTHER INFORMATION<\/h4>\n<\/li>\n
  • Administration of high doses in severe renal failure cautioned due to accumulation<\/li>\n
  • Dose frequency should not exceed once daily in renal impairment<\/li>\n
  • Has an active metabolite \u2013 diacetolol<\/li>\n","protected":false},"excerpt":{"rendered":"

    Acebutolol CLINICAL USE Beta-adrenoceptor blocker: Hypertension Angina Arrhythmias DOSE IN<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1602","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1602"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1602\/revisions"}],"predecessor-version":[{"id":2919,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1602\/revisions\/2919"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}